Elliott Builds $1.1B Stake in Bio-Rad to Boost Stock
0h ago|4 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
activist-investor
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Activist investment firm Elliott Investment Management has built a significant equity position in life-science tools company Bio-Rad Laboratories. The Wall Street Journal reported the stake on 18 May 2026, citing sources familiar with the matter. Elliott intends to push management to improve Bio-Rad’s stock performance. The activist's stake is estimated to be worth approximately $1.1 billion, representing a holding of over 10% in the $9.8 billion market capitalization company. Bio-Rad shares closed at $283.50 on 17 May, down 35% from a peak of over $430 reached in late 2025.
Activist investor campaigns in the life-science tools sector have a history of prompting major strategic shifts. In 2023, Dan Loeb’s Third Point targeted life-science firm Danaher, agitating for a spin-off of its environmental and applied solutions segment. That pressure contributed to Danaher's eventual separation into two publicly traded companies in 2025. The sector is currently navigating a post-pandemic normalization of demand, with many firms facing revenue headwinds after years of elevated growth.
Bio-Rad’s stock decline of over 35% from its 2025 highs created the valuation opportunity Elliott is exploiting. The company’s complex corporate structure, including a dual-class share system and significant non-operating assets, is a typical focus for activist scrutiny. Elliott’s entry follows a recent pattern of activists targeting healthcare companies perceived as undervalued due to operational or structural inefficiencies rather than core business failure.
Bio-Rad’s market capitalization stood at $9.8 billion as of the 17 May close. The stock trades at a price-to-earnings ratio of 12.5, a 40% discount to the peer group median P/E of 20.8 for the S&P 500 Life Sciences Tools & Services index. The company reported Q1 2026 revenue of $680 million, a decline of 9% year-over-year. Gross margin contracted 210 basis points to 54.1% in the same period.
A pre/post-campaign comparison shows the typical impact. In the 90 days following Elliott’s initial stake disclosure in a comparable 2024 campaign, the target company's stock outperformed the Russell 3000 by an average of 8.7 percentage points. Bio-Rad holds over $2.3 billion in cash, cash equivalents, and short-term investments as of 31 March 2026, a figure representing 23% of its total assets.
| Metric | Bio-Rad (BIO) | Peer Median (IHE) |
|---|---|---|
| P/E Ratio | 12.5 | 20.8 |
| Net Cash / Market Cap | 23% | 12% |
| 1-Year Stock Return | -35% | -15% |
The discrepancy between Bio-Rad’s cash-rich balance sheet and its discounted valuation is a primary data point underpinning the activist thesis.
The immediate second-order effect is a re-rating potential for peer companies perceived as similarly undervalued. Stocks like Agilent Technologies (A) and Bruker Corporation (BRKR) may see positive sentiment, with potential gains of 2-5% as investors screen for other cash-rich life-science tools companies. Conversely, companies with recent activist settlements, such as Illumina (ILMN), may experience selling pressure as capital rotates toward new, more immediate opportunities.
A key risk to the activist thesis is Bio-Rad's reliance on sales of COVID-19-related products, which have dissipated. A fundamental operational turnaround may be required beyond balance sheet optimization. The Elliott campaign is likely to attract long-biased hedge fund flow into the stock and related options. Short interest in BIO, at 4.2% of float, is relatively low, suggesting limited immediate squeeze potential but room for new long positioning.
The primary catalyst is the formal 13D filing with the U.S. Securities and Exchange Commission, which will detail Elliott’s exact stake and intentions. This filing is required within 10 days of crossing the 5% ownership threshold. Bio-Rad’s next earnings call, scheduled for 5 August 2026, will be a critical forum for management to address strategic plans.
Key technical levels for BIO stock include major support at $250, the stock's 2023 low, and initial resistance at the 200-day moving average near $310. A successful activist campaign typically involves a strategic review announcement within 90 days of the initial 13D filing. Investors should monitor for updates on potential asset sales, capital return programs, or board refreshment.
Elliott Investment Management, led by Paul Singer, frequently advocates for operational improvements, strategic reviews, board changes, and enhanced capital return to shareholders. In technology and healthcare, its campaigns have led to major corporate separations, such as the split of Hewlett Packard Enterprise and sales of non-core assets. The firm's playbook often involves a detailed public presentation outlining specific financial and operational targets for the company to meet.
Bio-Rad has a dual-class share structure with Class A and Class B shares, where the founding Schwartz family holds super-voting Class B shares. This structure can insulate management from external pressure, as activists typically need to persuade these controlling shareholders. Elliott's success will likely depend on engaging directly with the Schwartz family to align on value-creation strategies, rather than relying solely on a proxy contest to win board seats.
According to data from Activist Insight, approximately 65% of activist campaigns targeting U.S. healthcare companies between 2020 and 2025 resulted in some form of settlement or concession from management. These settlements most commonly involved adding new independent directors (42% of cases), initiating a strategic review (35%), or increasing share buybacks (28%). Full sale of the company occurred in roughly 15% of settled campaigns.
Elliott’s stake creates a tangible catalyst for closing Bio-Rad’s persistent valuation gap through strategic or financial engineering.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.